North Tide Capital’s Teva Pharmaceuticals TEVA Stock Holding History

North Tide Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,000,000	Closed	-$53.5M	–	21
2016 Q1	$53.5M	Hold	1,000,000	–	–	5.79%	7
2015 Q4	$65.6M	Sell	1,000,000 -1,700,000	-63%	-$105M	6.53%	7
2015 Q3	$152M	Sell	2,700,000 -300,000	-10%	-$19.5M	13.29%	2
2015 Q2	$177M	Buy	3,000,000 +1,500,000	+100%	+$92.5M	12.8%	2
2015 Q1	$93.5M	Sell	1,500,000 -1,500,000	-50%	-$87.2M	7.07%	4
2014 Q4	$173M	Buy	3,000,000 +1,000,000	+50%	+$55.7M	11.59%	2
2014 Q3	$108M	Sell	2,000,000 -1,000,000	-33%	-$53M	8.19%	2
2014 Q2	$157M	Hold	3,000,000	–	–	11%	2
2014 Q1	$159M	Buy	3,000,000 +250,000	+9%	+$11.6M	13.35%	2
2013 Q4	$110M	Buy	2,750,000 +425,000	+18%	+$16.7M	9.66%	1
2013 Q3	$87.8M	Buy	2,325,000 +1,225,000	+111%	+$47.8M	9.21%	2
2013 Q2	$43.1M	Buy	+1,100,000	New	+$42.8M	7.64%	5

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

North Tide Capital's TEVA Position: Q2 2016 in Review

North Tide Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 1,000,000 shares — an estimated $53.5M sold.

North Tide Capital first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $177M in Q2 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

North Tide Capital reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
North Tide Capital sold 1,000,000 Teva Pharmaceuticals shares in Q2 2016, an estimated $53.5M.
North Tide Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
North Tide Capital's Teva Pharmaceuticals position peaked at $177M in Q2 2015.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on North Tide Capital's 13F filing for Q2 2016, filed 15 Aug 2016.